Published in Ann Oncol on January 01, 2004
The immune response to tumors as a tool toward immunotherapy. Clin Dev Immunol (2011) 0.91
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon? J Carcinog (2013) 0.87
A quest for therapeutic antigens in bone and soft tissue sarcoma. J Transl Med (2005) 0.85
Lung cancer vaccines. Cancer J (2011) 0.82
Phage display--a powerful technique for immunotherapy: 2. Vaccine delivery. Hum Vaccin Immunother (2012) 0.76
Protective antitumor immunity induced by tumor cell lysates conjugated with diphtheria toxin and adjuvant epitope in mouse breast tumor models. Chin J Cancer (2012) 0.75
Retracted Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med (2000) 2.64
Proteasome inhibitors: antitumor effects and beyond. Leukemia (2006) 1.87
Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus. J Gen Virol (2000) 1.60
Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer (2010) 1.37
Antibody-dependent killing of tumor cells by polymorphonuclear leukocytes. Involvement of oxidative and nonoxidative mechanisms. J Natl Cancer Inst (1984) 1.07
Inactivation of neutrophil-derived hypochlorous acid by nimesulide: a potential mechanism for the tissue protection during inflammation. Int J Tissue React (1990) 1.07
Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes. Acta Haematol (1993) 1.05
Immunomodulatory effects of anti-angiogenic drugs. Leukemia (2011) 1.02
Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother (2005) 1.01
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol (2008) 1.01
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol (2004) 1.00
Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J Clin Oncol (1999) 0.98
Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma. Clin Dev Immunol (2012) 0.98
Mechanisms of tumour cell destruction by PMA-activated human neutrophils. Immunology (1983) 0.97
Inhibition of neutrophil cytolysin production by target cells. Blood (1986) 0.96
Post-transcriptional regulation of adapter molecules by IL-10 inhibits TLR-mediated activation of antigen-presenting cells. Leukemia (2008) 0.92
Defective antibody-dependent tumour cell lysis by neutrophils from cancer patients. Clin Exp Immunol (1989) 0.92
Immune regulatory loops determine productive interactions within human T lymphocyte-dendritic cell clusters. Proc Natl Acad Sci U S A (1999) 0.91
Relationship between antibody-dependent tumour cell lysis and primary granule exocytosis by human neutrophils. Clin Exp Immunol (1987) 0.91
T-cell receptor beta variable region diversity in melanoma metastases after interleukin 2-based immunotherapy. Clin Cancer Res (1996) 0.90
Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther (2003) 0.89
Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond. Curr Cancer Drug Targets (2012) 0.89
Tumor cell lysis by activated human neutrophils: analysis of neutrophil-delivered oxidative attack and role of leukocyte function-associated antigen 1. Inflammation (1991) 0.88
Neutrophil-induced depletion of adenosine triphosphate in target cells: evidence for a hypochlorous acid-mediated process. J Lab Clin Med (1988) 0.87
Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method. Cancer Res (1998) 0.87
Augmentation of neutrophil-mediated erythrocyte lysis by cells derived in vitro from human monocytes. Blood (1987) 0.86
Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. Clin Exp Immunol (2014) 0.86
A multi-scale approach to colorectal cancer: from a biochemical- interaction signaling-network level, to multi-cellular dynamics of malignant transformation. Interplay with mutations and onco-protein inhibitor drugs. Curr Cancer Drug Targets (2012) 0.85
Effects of ascorbic acid on neutrophil locomotion. Int Arch Allergy Appl Immunol (1980) 0.85
Antibody-dependent tumour cytolysis by human neutrophils: effect of synthetic serine esterase inhibitors and substrates. Immunology (1987) 0.85
Reverse-transcriptase polymerase chain reaction of the maspin gene in the detection of bone marrow breast carcinoma cell contamination. Cancer (2001) 0.84
Down-regulation of K cell activity by neutrophils. Blood (1985) 0.84
Ox erythrocyte cytotoxicity by phorbol myristate acetate-activated human neutrophils. Scand J Immunol (1983) 0.84
Erythrocyte lysis by PMA-triggered neutrophil polymorphonuclears: evidence for an hypochlorous acid-dependent process. Immunology (1985) 0.84
Evidence for a reversible functional state of neutrophil chemotactic deactivation. Int Arch Allergy Appl Immunol (1980) 0.84
Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera. Leukemia (2006) 0.84
Serum-associated inhibition of neutrophil Fc receptors in cancer patients. J Natl Cancer Inst (1981) 0.84
Neutrophil-mediated cellular cytotoxicity triggered by immobilized aggregated IgG: an in vitro model of cell injury during immune complex diseases. J Clin Immunol (1984) 0.84
Neutrophil dysfunction and repeated infections: influence of levamisole and ascorbic acid. Br J Dermatol (1980) 0.83
Role of the oxidative metabolic burst in the antibody-dependent cellular cytotoxicity mediated by neutrophil polymorphonuclears. Exp Hematol (1982) 0.83
Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients. Int J Lab Hematol (2009) 0.83
High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica (1997) 0.83
Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma. J BUON (2011) 0.82
Stimulation of neutrophil chemotaxis, adhesiveness, phagocytosis, and hexose monophosphate shunt activity by N-(2-mercaptopropionyl)glycine. Res Exp Med (Berl) (1981) 0.82
Neutrophil functions in acne conglobata. Dermatologica (1979) 0.82
In vitro effects of synthetic chemotactic peptides on neutrophil function. Int Arch Allergy Appl Immunol (1980) 0.82
Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARgamma ligand troglitazone. Cell Mol Life Sci (2009) 0.82
Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells. Br J Haematol (2001) 0.82
Role of angiogenesis inhibitors in colorectal cancer: sensitive and insensitive tumors. Curr Cancer Drug Targets (2012) 0.82
Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer. Curr Cancer Drug Targets (2012) 0.82
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia (2016) 0.81
Neutropenia and impaired neutrophil function in glycogenosis type Ib. J Inherit Metab Dis (1984) 0.81
Ultrasonography-guided endoscopic stent placement for malignant biliary obstruction: a preliminary report of four cases. Endoscopy (2004) 0.81
Dendritic cell-based vaccines in patients with hematological malignancies. Ann N Y Acad Sci (2001) 0.80
Reversal by cimetidine of histamine-induced inhibition of true chemotaxis in neutrophil polymorphonuclears. Res Exp Med (Berl) (1980) 0.80
Zoledronic acid inhibits the function of Toll-like receptor 4 ligand activated monocyte-derived dendritic cells. Leukemia (2007) 0.80
The induction of distinct cytokine cascades correlates with different effects of granulocyte-colony stimulating factor and granulocyte/macrophage-colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for breast cancer. Cancer Immunol Immunother (1999) 0.80
Defective neutrophil chemotaxis corrected by levamisole in Crohn's disease. Acta Hepatogastroenterol (Stuttg) (1978) 0.80
A monoclonal antibody to platelet glycoproteins IIb and IIIa complex: its use in purifying human megakaryocytes from sternal bone marrow aspirates for immunofluorescence studies of Ia-like antigens. Exp Hematol (1983) 0.80
Characterization of BAX inhibitor-1 as a novel leukemia-associated antigen. Leukemia (2009) 0.80
High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma. Int J Oncol (2000) 0.79
Erythrocyte lysis by monocytes: investigations on the mechanism and role of the target cell hydrogen peroxide catabolizing pathways. J Clin Lab Immunol (1987) 0.79
Extracellular cytotoxicity by phagocytosing polymorphonuclear neutrophilic leukocytes: enhancement by a chemotactic stimulus. Exp Hematol (1985) 0.79
Modulation of neutrophil Fc and C3b receptors. Relationship with the phagocytic process and activation of the respiratory burst. Inflammation (1983) 0.78
Fluorescence in situ hybridization provides evidence for two-step rearrangement in a masked Ph chromosome formation. Leuk Res (1995) 0.78
Platelets as inhibitory cells in neutrophil-mediated cytolysis. J Lab Clin Med (1989) 0.78
High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule. Br J Cancer (1997) 0.78
[Ultrasound-guided endoscopic drainage, without radiological examination, in patients with neoplastic biliary obstruction. Preliminary results]. Minerva Chir (2004) 0.77
High frequency of trisomy 8 in acute promyelocytic leukemia: a fluorescence in situ hybridization study. Cancer Genet Cytogenet (1997) 0.77
Platelets as scavengers of neutrophil-derived oxidants: a possible defence mechanism at sites of vascular injury. Thromb Haemost (1989) 0.77
Serum cytokine levels in cancer patients treated with different schedules of ultra-low-dose interleukin-2. J Immunother Emphasis Tumor Immunol (1994) 0.77
Stimulation of granulocyte adhesiveness by the chemotactic peptide N-formyl-L-methionyl-L-phenylalanine. Res Exp Med (Berl) (1980) 0.77
Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study. Cancer Immunol Immunother (1993) 0.77
Approaches to dendritic cell-based immunotherapy after peripheral blood stem cell transplantation. Ann N Y Acad Sci (1999) 0.77
Direct effects of protirelin (TRH) on cultured porcine thyrocytes. J Endocrinol Invest (1992) 0.77
Effect of different cytokines on mammaglobin and maspin gene expression in normal leukocytes: possible relevance to the assays for the detection of micrometastatic breast cancer. Br J Cancer (2005) 0.77
Development of novel compounds to treat autoimmune and inflammatory diseases and graft versus host reactions. Endocr Metab Immune Disord Drug Targets (2007) 0.77
MOF induced by meningococcal sepsis: successful outcome after intensive multidisciplinary approaches. Transfus Apher Sci (2005) 0.76
Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals. Infection (2013) 0.76
New perspectives in dendritic cell-based cancer immunotherapy. BioDrugs (2001) 0.76
Effects of ascorbic acid on neutrophil function. Studies on normal and chronic granulomatous disease neutrophils. Acta Vitaminol Enzymol (1982) 0.76
Defective neutrophil mobilization to skin chambers in cancer patients. J Cancer Res Clin Oncol (1984) 0.76
IgA-related defective neutrophil chemotaxis in ulcerative colitis. Boll Ist Sieroter Milan (1978) 0.76
Induction of minor histocompatiblity antigen HA-1-specific cytotoxic T cells for the treatment of leukemia after allogeneic stem cell transplantation. Blood (1999) 0.76
Restriction of T cell receptor V beta repertoire in melanoma metastasis responding to immunotherapy. Melanoma Res (1995) 0.76
High-dose chemotherapy plus hematopoietic stem-cell rescue for metastatic breast cancer. N Engl J Med (2000) 0.75
Prevention of neutrophil chemotactic deactivation by ascorbic acid. Br J Exp Pathol (1980) 0.75
Interference of target cell catalase with an early step of the neutrophil cytolytic pathway. Clin Exp Immunol (1986) 0.75
Disorders of neutrophil function in children with recurrent pyogenic infections. Med Microbiol Immunol (1982) 0.75
Neutrophil-mediated antibody-dependent cellular cytotoxicity against erythrocytes. Mechanisms of target cell destruction. Clin Exp Immunol (1983) 0.75
Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF. J Clin Oncol (1999) 0.75
Chemotactic peptide enhancement of PMA triggered monocyte cytotoxicity. Clin Exp Immunol (1984) 0.75
Standard-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) allows safe and repeated administration of high-dose cyclophosphamide, etoposide, and cisplatin (CEP). Am J Clin Oncol (1997) 0.75
[Platelet preservation for blood transfusion. Morphological ultrastructural evaluation of platelets exposed to various concentrations of dimethyl sulfoxide (DMSO)]. Riv Emoter Immunoematol (1974) 0.75
[Platelet dynamics in splenectomized patients]. Riv Emoter Immunoematol (1974) 0.75
[Essential thrombocytemia, Hematological, clinical and dynamic aspects in 5 cases]. Haematologica (1972) 0.75
[Platelet preservation for blood transfusion. Effects of dimethyl sulfoxide (DMSO) on platelet function in vitro]. Riv Emoter Immunoematol (1974) 0.75